Non-CML Myeloproliferative Diseases, An Issue of Hematology/Oncology Clinics of North America, 1st Edition
著者 :
By Ross Levine, MD
Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies in M
...view more
Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies in MPNs; Role of novel mutations in MPN pathogenesis and outcome; Role of JAK inhibitors in MPN treatment; Animal Models of MPNs; and Role of Germline Genetic Factors in MPN Pathogenesis.
Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies in MPNs; Role of novel mutations in MPN pathogenesis and outcome; Role of JAK inhibitors in MPN treatment; Animal Models of MPNs; and Role of Germline Genetic Factors in MPN Pathogenesis.
著者情報
By Ross Levine, MD, Memorial SloHuman Oncology and Pathogenesis Program.
Department of Medicine, Leukemia Service,
Memorial Sloan Kettering Cancer Center,
New York, New York, USA.an-Kettering Cancer Center
By Ross Levine, MD, Memorial SloHuman Oncology and Pathogenesis Program.
Department of Medicine, Leukemia Service,
Memorial Sloan Kettering Cancer Center,
New York, New York, USA.an-Kettering Cancer Center
https://shop.elsevier.jp/non-cml-myeloproliferative-diseases-an-issue-of-hematologyoncology-clinics-of-north-america-9781455747641.html319746Non-CML Myeloproliferative Diseases, An Issue of Hematology/Oncology Clinics of North Americahttps://secure-ecsd.elsevier.com/covers/80/Tango2/large/9781455747641.jpg10674.312558JPYInStock/Medicine/Oncology/eBooks/Medicine/Oncology/Medicine/Oncology/eBooks/Product Format/E-Book/Product Format/E-Book/Product Format/E-Book505458550546655803588525986752550405936800593682759368321488653650545535799892580352651451205259833593679959368235936828Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies in MPNs; Role of novel mutations in MPN pathogenesis and outcome; Role of JAK inhibitors in MPN treatment; Animal Models of MPNs; and Role of Germline Genetic Factors in MPN Pathogenesis. Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies in MPNs; Role of novel mutations in MPN pathogenesis and outcome; Role of JAK inhibitors in MPN treatment; Animal Models of MPNs; and Role of Germline Genetic Factors in MPN Pathogenesis.00add-to-cart97814557476412012専門医By Ross Levine, MD20121E-BookSaunders02012/10/28IN STOCKBy <STRONG>Ross Levine</STRONG>, MD, Memorial SloHuman Oncology and Pathogenesis Program.
Department of Medicine, Leukemia Service,
Memorial Sloan Kettering Cancer Center,
New York, New York, USA.an-Kettering Cancer CenterE-BookE-BookThe Clinics: Internal Medicine米国いいえYesYesいいえいいえ選択してください選択してくださいいいえいいえ選択してください
